Fresenius Medical Care stock (DE0005785802): Global leader in dialysis services

Fresenius Medical Care, a top provider of dialysis products and services worldwide, maintains a strong position in the growing kidney care market. US investors track its performance amid rising chronic kidney disease prevalence.

Fresenius Medical Care operates over 4,100 dialysis clinics globally, treating more than 345,000 patients as of its latest annual report published in March 2025 covering 2024. The company reported revenue of €21.5 billion for 2024, up 3% year-over-year, driven by its care delivery and machines segments, according to Annual Report as of 03/19/2025.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Fresenius Medical Care AG & Co. KGaA
• Sector/industry: Healthcare / Dialysis services and products
• Headquarters/country: Bad Homburg, Germany
• Core markets: North America, Europe, Asia-Pacific, Latin America
• Key revenue drivers: Dialysis services, machines, disposables
• Home exchange/listing venue: Frankfurt (FME), OTCQX (FMS)
• Trading currency: EUR (primary), USD (US)

Fresenius Medical Care: core business model

Fresenius Medical Care focuses on comprehensive kidney care, providing dialysis products, services, and related healthcare. Its integrated model spans manufacturing dialysis machines and disposables to operating clinics, serving end-stage renal disease patients. In 2024, care delivery accounted for 74% of revenue at €15.9 billion, per the annual report cited above.

The company's value creation centers on a global network, with North America contributing 37% of revenue. It emphasizes digital health solutions like the 360° CARE initiative for patient monitoring, enhancing outcomes and efficiency for US investors eyeing medtech exposure.

Main revenue and product drivers for Fresenius Medical Care

Dialysis services form the backbone, with recurring revenue from treatments using proprietary consumables. Key products include 4008S and 5008S CorDi machines, which optimize water and energy use. Machines and disposables generated €5.6 billion in 2024, supported by innovation in hemodiafiltration.

US market leadership via 2,600+ clinics positions it for Medicare reimbursement trends. Growth drivers include home dialysis expansion, with products like NxStage System One, aligning with US policy shifts toward outpatient care.

Industry trends and competitive position

The global dialysis market, valued at $100 billion in 2024 per Statista as of 01/2025, grows at 5-7% annually due to aging populations and diabetes prevalence. Fresenius holds 30-35% share in services, competing with Baxter and Nipro.

In the US, where ESRD affects 800,000 patients, its scale provides bargaining power with payers. Competitive edges include R&D spend of €400 million in 2024 and a shift to sustainable practices, like reduced-plastic dialyzers.

Why Fresenius Medical Care matters for US investors

Listed on OTCQX as FMS, it offers US investors access to Europe's largest dialysis provider with 37% revenue from North America. Exposure to US healthcare spending, projected at $4.5 trillion in 2024 by CMS data published 2025, ties its fortunes to Medicare Advantage trends.

Its US clinic network benefits from bundled payment models, providing stability amid policy volatility relevant to American portfolios.

Conclusion

Fresenius Medical Care sustains a robust model in kidney care, with steady revenue growth and US-centric operations. Investors monitor clinic expansions and product pipelines amid demographic tailwinds. Market dynamics, including reimbursement and competition, shape its trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.